• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Elicit Plant Appoints Pam Marrone and Johan de Saegher on Its Board of Directors

    3/1/23 5:30:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATNF alert in real time by email
    • Pam Marrone joins as Chairwoman of the Board of Directors and Johan de Saegher as Independent Board Member

    Elicit Plant, an agricultural biotechnology company specialized in crops' resistance to water stress based on a phytosterol-based technology platform, announced today it has appointed Dr. Pam Marrone as Chairwoman of the Board of Directors and Dr. Johan de Saegher as Independent Board Member.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230301005582/en/

    Pam Marrone and Johan de Saegher join Elicit Plant's Board of Directors (Photo: Elicit Plant)

    Pam Marrone and Johan de Saegher join Elicit Plant's Board of Directors (Photo: Elicit Plant)

    Pam is a serial entrepreneur bringing over 30 years of leadership experience in the agricultural biologicals industry. Pam currently serves as Executive Chair of Invasive Species Control Corporation which she cofounded in 2022. Recently, she was Chief Executive Officer of Marrone Bio Innovations (MBI), an agricultural biological company she founded in 2006. In 2013, MBI listed its stock on NASDAQ. Under her leadership, the company commercialized 10 products from six EPA-registered active ingredients, and in 2019 acquired ProFarm Technologies selling bionutrient seed treatments from wood waste. Prior to establishing MBI, Marrone founded AgraQuest in 1995, where she served as CEO, Chairwoman or President until 2006. Pam is a well-recognized leader as evidenced by numerous awards, including the American Chemical Society's "Kathryn C. Hach Award for Entrepreneurial Success," "Most Admired CEO, Distinguished Career Award" by the Sacramento Business Journal, the "Sustie" award by the Ecological Farming Association, and the Natural Resources Defense Council (NRDC) Growing Green Award in the "Business Leader" category. Pam is the founder of the Biological Products Industry Alliance, now a trade group of more than 100 companies. Aside from her role as Chairwoman of Elicit Plant, Pam serves on several for-profit and non-profit Boards, including 180 Life Sciences (NASDAQ:ATNF), StemExpress, Pheronym and the Foundation for Food and Agriculture Research.

    Johan de Saegher is an accomplished business executive with 30 years of business experience of which 17 years in the crop protection industry. He currently serves as CEO of Bi-PA, a company specialized in developing innovative solutions for pest management. From 2018 to 2022 he held the position of CEO and COO of Belchim Crop Protection NV, a leading European distributor in the crop protection market, based in Belgium, with also activities in North America and Asia. Previously, and until the company was acquired by Eastman Chemical in 2014, Johan worked at Taminco (NYSE) where he held positions as Chief Operating Officer, Vice-President Agrosciences and President Asia/Latin America. He is currently also Chairman of Aphea.bio and holds a board position within Mitsui Agrisciences International.

    "I am impressed by the excellent achievements Elicit Plant has accomplished in such a short time. The company's unique technology platform positively impacts the planet and provides farmers with a natural and efficient solution to address the challenges of climate change. I am looking forward to work alongside the team as it accelerates its growth," said Pam Marrone.

    Johan de Saegher added, "It is an honor to join Elicit Plant's Board of Directors and contribute to building the company into a large scale and profitable enterprise as it is entering its next phase of development. Through its high value solutions, Elicit Plant offers for row crops a new dimension in abiotic stress management such as drought, safeguarding the yield of the farmer by optimizing the natural response of the plants to the changing environment."

    Jean-François Dechant, Chief Executive Officer and Cofounder of Elicit Plant, said: "Pam and Johan are a wonderful addition as Elicit Plant is entering new markets, expanding its laboratories and diversifying its portfolio of products. At such a strategic time for Elicit Plant, we are grateful for their confidence, and we are all eager to benefit from their knowledge and impressive track records."

    About Elicit Plant

    Elicit Plant is an agbiotech company created in 2017 with the ambition to become a sustainability transition champion in agriculture and respond to the global challenges of water stress in crops. Based in Charente (France), the firm has 60 employees across its R&D Center established within a 1,000 ha farm, its offices in Lyon, and its subsidiary in Brazil. Elicit Plant's proprietary technology is delivered through foliar application of phytosterols, molecules found in plants that reduce crops' water consumption. Open-field trials have shown an average yield increase of +10 bushels per acre on average. In 2022, Elicit Plant began marketing its BEST-a product line for corn crops in France, and obtained market approvals for Ukraine and Brazil.

    For more information: www.elicit-plant.com

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230301005582/en/

    Get the next $ATNF alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATNF

    DatePrice TargetRatingAnalyst
    9/15/2021$11.00Buy
    Maxim Group
    More analyst ratings

    $ATNF
    SEC Filings

    See more
    • SEC Form S-3 filed by 180 Life Sciences Corp.

      S-3 - 180 Life Sciences Corp. (0001690080) (Filer)

      5/9/25 4:15:31 PM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by 180 Life Sciences Corp.

      10-K/A - 180 Life Sciences Corp. (0001690080) (Filer)

      5/8/25 4:20:24 PM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 180 Life Sciences Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - 180 Life Sciences Corp. (0001690080) (Filer)

      5/1/25 9:18:16 AM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Jordan Blair acquired 1,318,000 shares (SEC Form 4)

      4 - 180 Life Sciences Corp. (0001690080) (Issuer)

      4/30/25 5:57:06 PM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Elray Resources, Inc. converted options into 1,318,000 shares (SEC Form 4)

      4 - 180 Life Sciences Corp. (0001690080) (Issuer)

      4/11/25 6:05:04 PM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Jordan Blair acquired 200,000 shares (SEC Form 4)

      4 - 180 Life Sciences Corp. (0001690080) (Issuer)

      4/2/25 4:59:04 PM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNF
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 180 Life Sciences Corp. Announces Pricing of $2.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under NASDAQ Rules

      PALO ALTO, CA / ACCESSWIRE / December 27, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF), a biotechnology company that is currently refocusing its business on the international entertainment and iGaming sector, today announced that it has entered into a securities purchase agreement with several institutional investors to sell 1,200,000 shares of common stock in a registered direct offering priced at market under Nasdaq rules. In a concurrent private placement, the Company also agreed to issue unregistered warrants to purchase up to an aggregate of 1,200,000 shares of common stock. The combined effective offering price for each share of common stock and accompanying wa

      12/27/24 9:00:00 AM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 180 Life Sciences Corp. Regains Full Compliance with Nasdaq Continued Listing Rules

      PALO ALTO, CA / ACCESSWIRE / December 12, 2024 / 180 Life Sciences Corp. ("180" or the "Company") is pleased to announce that it has regained compliance with Nasdaq Listing Rule 5605(c)(2), which requires Nasdaq listed companies to maintain an audit committee consisting of three independent directors. This development follows the recent appointment of Mr. Stephen Shoemaker as an independent director of the Company and as a member of the Company's audit committee. With this appointment, 180 is now in full compliance with all Nasdaq continued listing requirements and has remedied all previously announced deficiencies.Mr. Blair Jordan, Interim CEO of the Company, stated, "This brings 180 into f

      12/12/24 8:00:00 AM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors

      PALO ALTO, CA / ACCESSWIRE / December 4, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF), a biotechnology company that is currently refocusing its business on the international entertainment and iGaming sector, today announced the appointment of Stephen Shoemaker to its Board of Directors, effective December 3, 2024.Mr. Shoemaker brings to 180 a wealth of experience as a seasoned senior executive and board member with a diverse background spanning finance, operations management, capital raising, and strategic planning. With over $2 billion in capital raised during his tenure in both CEO and CFO roles across four companies, Mr. Shoemaker has consistently demonstrated his

      12/4/24 8:00:00 AM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $ATNF
    Financials

    Live finance-specific insights

    See more

    $ATNF
    Leadership Updates

    Live Leadership Updates

    See more

    $ATNF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13G/A filed by 180 Life Sciences Corp.

      SC 13G/A - 180 Life Sciences Corp. (0001690080) (Subject)

      11/14/24 3:53:30 PM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by 180 Life Sciences Corp.

      SC 13G - 180 Life Sciences Corp. (0001690080) (Subject)

      10/18/24 5:00:02 PM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by 180 Life Sciences Corp.

      SC 13G - 180 Life Sciences Corp. (0001690080) (Subject)

      2/14/24 3:27:19 PM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 180 Life Sciences Corp. - Corporate Updates

      Announcing Acquisition of Advanced Gaming Technology Platform, Positive Progress on Legacy CBD Formulation, and Strengthened Balance SheetPALO ALTO, CA / ACCESSWIRE / October 3, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF) (the "Company" or "180") is pleased to provide a corporate update covering several key initiatives.CORPORATE UPDATE HIGHLIGHTS:Company shifts focus and enters global iGaming market - completes a significant technology acquisitionExpected Compliance with Nasdaq Listing Rule 5550(b)(1) - Company expects to meet Nasdaq continued listing requirement which requires maintenance of stockholders' equity of at least $2.5 millionPositive Study Results on CBD Pill Forms - 180 achieve

      10/3/24 8:30:00 AM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 180 Life Sciences Corp. Regains Full Compliance with Nasdaq Continued Listing Rules

      PALO ALTO, CA / ACCESSWIRE / December 12, 2024 / 180 Life Sciences Corp. ("180" or the "Company") is pleased to announce that it has regained compliance with Nasdaq Listing Rule 5605(c)(2), which requires Nasdaq listed companies to maintain an audit committee consisting of three independent directors. This development follows the recent appointment of Mr. Stephen Shoemaker as an independent director of the Company and as a member of the Company's audit committee. With this appointment, 180 is now in full compliance with all Nasdaq continued listing requirements and has remedied all previously announced deficiencies.Mr. Blair Jordan, Interim CEO of the Company, stated, "This brings 180 into f

      12/12/24 8:00:00 AM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors

      PALO ALTO, CA / ACCESSWIRE / December 4, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF), a biotechnology company that is currently refocusing its business on the international entertainment and iGaming sector, today announced the appointment of Stephen Shoemaker to its Board of Directors, effective December 3, 2024.Mr. Shoemaker brings to 180 a wealth of experience as a seasoned senior executive and board member with a diverse background spanning finance, operations management, capital raising, and strategic planning. With over $2 billion in capital raised during his tenure in both CEO and CFO roles across four companies, Mr. Shoemaker has consistently demonstrated his

      12/4/24 8:00:00 AM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 180 Life Sciences Corp. Appoints Mr. Jay Goodman to Board of Directors

      PALO ALTO, CA / ACCESSWIRE / October 29, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF) today announced the appointment of Mr. Jay Goodman to its Board of Directors, effective immediately. Mr. Goodman brings over a decade of expertise in the software-as-a-service (SaaS) and iGaming industries, along with more than seven years of experience in executive leadership roles. Mr. Goodman's distinguished career includes contributions to several high-growth companies, successful IPOs, and extensive work in the Asia Pacific and Japan markets.Currently, Mr. Goodman serves as Sales Director for Asia Pacific and Japan at Docker, Inc., a position he has held since January 2024. Doc

      10/29/24 8:00:00 AM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on 180 Life Sciences Corp. with a new price target

      Maxim Group initiated coverage of 180 Life Sciences Corp. with a rating of Buy and set a new price target of $11.00

      9/15/21 7:48:59 AM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Woody James N. bought $4,700 worth of shares (25,000 units at $0.19), increasing direct ownership by 60% to 66,888 units (SEC Form 4)

      4 - 180 Life Sciences Corp. (0001690080) (Issuer)

      12/18/23 4:15:16 PM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care